Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Systematic Review Article

Serious Adverse Events Have Not Been Reported with Spinal Intrathecal Injection of Mesenchymal Stem Cells: A Systematic Review

Author(s): Amir Barmada, Joshua Sharan, Nicolas Band and Chadwick Prodromos*

Volume 18, Issue 6, 2023

Published on: 16 September, 2022

Page: [829 - 833] Pages: 5

DOI: 10.2174/1574888X17666220817125324

Price: $65

Abstract

Background: Mesenchymal stem cells (MSCs) are partially differentiated multipotent cells. They can be derived from various tissues such as the umbilical cord, bone marrow, and adipose tissue. Intrathecal administration of MSCs has shown efficacy for various neurological conditions including multiple sclerosis, autism, traumatic brain injury, and many more.

Objective: This review will seek to determine whether there are any serious adverse events associated with spinal intrathecal administration of MSCs.

Methods: PubMed was used to search the scientific literature for serious adverse events that are related to spinal intrathecal administration of MSCs. Disease specific searches were performed for neurological conditions that could benefit from intrathecal administration of MSCs. In addition, a general serious adverse events search was performed to identify any additional adverse events.

Results and Discussion: A total of 39 studies were included in our analysis. None of the studies reported serious adverse events related to spinal intrathecal administration of MSCs. Notably, no infections, clinical rejection, or tumors were identified.

Conclusion: Properly performed spinal intrathecal injection of MSCs is exceedingly safe, with no serious adverse events reported based on our exhaustive literature search.

Keywords: Mesenchymal stem cell, stem cell, umbilical cord, bone marrow, serious adverse events, neurological diseases.

Graphical Abstract
[1]
Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - Current trends and future prospective. Biosci Rep 2015; 35(2): e00191.
[http://dx.doi.org/10.1042/BSR20150025] [PMID: 25797907]
[2]
Lin W, Xu L, Zwingenberger S, Gibon E, Goodman SB, Li G. Mesenchymal stem cells homing to improve bone healing. J Orthop Translat 2017; 9: 19-27.
[http://dx.doi.org/10.1016/j.jot.2017.03.002] [PMID: 29662796]
[3]
Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells 2019; 8(8): 784.
[http://dx.doi.org/10.3390/cells8080784] [PMID: 31357692]
[4]
Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 2013; 45(11): e54.
[http://dx.doi.org/10.1038/emm.2013.94] [PMID: 24232253]
[5]
Ra JC, Shin IS, Kim SH, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 2011; 20(8): 1297-308.
[http://dx.doi.org/10.1089/scd.2010.0466] [PMID: 21303266]
[6]
Wang L, Li Y, Xu M, et al. Regulation of inflammatory cytokine storms by mesenchymal stem cells. Front Immunol 2021; 12: 726909.
[http://dx.doi.org/10.3389/fimmu.2021.726909] [PMID: 34394132]
[7]
Barczewska M, Maksymowicz S, Zdolińska-Malinowska I, Siwek T, Grudniak M. Umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis: An original study. Stem Cell Rev Rep 2020; 16(5): 922-32.
[http://dx.doi.org/10.1007/s12015-020-10016-7] [PMID: 32725316]
[8]
Petrou P, Kassis I, Yaghmour NE, Ginzberg A, Karussis D. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. Front Biosci 2021; 26(10): 693-706.
[http://dx.doi.org/10.52586/4980] [PMID: 34719198]
[9]
Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain 2020; 143(12): 3574-88.
[http://dx.doi.org/10.1093/brain/awaa333] [PMID: 33253391]
[10]
Lv YT, Zhang Y, Liu M, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med 2013; 11(1): 196.
[http://dx.doi.org/10.1186/1479-5876-11-196] [PMID: 23978163]
[11]
Wang S, Cheng H, Dai G, et al. Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury. Brain Res 2013; 1532: 76-84.
[http://dx.doi.org/10.1016/j.brainres.2013.08.001] [PMID: 23942181]
[12]
Alstadhaug KB, Odeh F, Baloch FK, Berg DH, Salvesen R. Post-lumbar puncture headache. Tidsskr Nor Laegeforen 2012; 132(7): 818-21.
[http://dx.doi.org/10.4045/tidsskr.11.0832]
[13]
Cognat E, Koehl B, Lilamand M, et al. Preventing post-lumbar puncture headache. Ann Emerg Med 2021; 78(3): 443-50.
[http://dx.doi.org/10.1016/j.annemergmed.2021.02.019] [PMID: 33966935]
[14]
Evans RW. Complications of lumbar puncture. Neurol Clin 1998; 16(1): 83-105.
[http://dx.doi.org/10.1016/S0733-8619(05)70368-6] [PMID: 9421542]
[15]
Prodromos C, Rumschlag T. Administration of autologous mesenchymal cells for the treatment of arthritis. Curr Stem Cell Res Ther 2021; 16(8): 931-8.
[http://dx.doi.org/10.2174/1574888X16666210224145104] [PMID: 33655846]
[16]
Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11(2): 150-6.
[http://dx.doi.org/10.1016/S1474-4422(11)70305-2] [PMID: 22236384]
[17]
Huang L, Zhang C, Gu J, et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant 2018; 27(2): 325-34.
[http://dx.doi.org/10.1177/0963689717729379] [PMID: 29637820]
[18]
Wang L, Wang L, Cong X, et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: Safety and efficacy. Stem Cells Dev 2013; 22(24): 3192-202.
[http://dx.doi.org/10.1089/scd.2013.0023] [PMID: 23941289]
[19]
Zhang J, Lv S, Liu X, Song B, Shi L. Umbilical cord mesenchymal stem cell treatment for Crohn’s Disease: A randomized controlled clinical trial. Gut Liver 2018; 12(1): 73-8.
[http://dx.doi.org/10.5009/gnl17035] [PMID: 28873511]
[20]
Skyler JS, Fonseca VA, Segal KR, Rosenstock J. Allogeneic mesenchymal precursor cells in type 2 diabetes: A randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care 2015; 38(9): 1742-9.
[http://dx.doi.org/10.2337/dc14-2830] [PMID: 26153271]
[21]
Llufriu S, Sepúlveda M, Blanco Y, et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One 2014; 9(12): e113936.
[http://dx.doi.org/10.1371/journal.pone.0113936] [PMID: 25436769]
[22]
Oh KW, Moon C, Kim HY, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med 2015; 4(6): 590-7.
[http://dx.doi.org/10.5966/sctm.2014-0212] [PMID: 25934946]
[23]
Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010; 67(10): 1187-94.
[http://dx.doi.org/10.1001/archneurol.2010.248] [PMID: 20937945]
[24]
Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology 2019; 93(24): e2294-305.
[http://dx.doi.org/10.1212/WNL.0000000000008620] [PMID: 31740545]
[25]
Mazzini L, Ferrero I, Luparello V, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Exp Neurol 2010; 223(1): 229-37.
[http://dx.doi.org/10.1016/j.expneurol.2009.08.007] [PMID: 19682989]
[26]
Siwek T, Jezierska-Woźniak K, Maksymowicz S, et al. Repeat administration of bone marrow-derived mesenchymal stem cells for treatment of amyotrophic lateral sclerosis. Med Sci Monit 2020; 26: e927484.
[http://dx.doi.org/10.12659/MSM.927484] [PMID: 33301428]
[27]
Rushkevich YN, Kosmacheva SM, Zabrodets GV, et al. The use of autologous mesenchymal stem cells for cell therapy of patients with amyotrophic lateral sclerosis in belarus. Bull Exp Biol Med 2015; 159(4): 576-81.
[http://dx.doi.org/10.1007/s10517-015-3017-3] [PMID: 26395626]
[28]
Syková E, Rychmach P, Drahorádová I, et al. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: Results of phase I/IIa clinical trial. Cell Transplant 2017; 26(4): 647-58.
[http://dx.doi.org/10.3727/096368916X693716] [PMID: 27938483]
[29]
Staff NP, Madigan NN, Morris J, et al. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology 2016; 87(21): 2230-4.
[http://dx.doi.org/10.1212/WNL.0000000000003359] [PMID: 27784774]
[30]
Oh KW, Noh MY, Kwon MS, et al. Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann Neurol 2018; 84(3): 361-73.
[http://dx.doi.org/10.1002/ana.25302] [PMID: 30048006]
[31]
Petrou P, Gothelf Y, Argov Z, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: Results of phase 1/2 and 2a clinical trials. JAMA Neurol 2016; 73(3): 337-44.
[http://dx.doi.org/10.1001/jamaneurol.2015.4321] [PMID: 26751635]
[32]
Bonab MM, Sahraian MA, Aghsaie A, et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: An open label study. Curr Stem Cell Res Ther 2012; 7(6): 407-14.
[http://dx.doi.org/10.2174/157488812804484648] [PMID: 23061813]
[33]
Harris VK, Stark JW, Yang S, Zanker S, Tuddenham J, Sadiq SA. Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study. Neurol Neuroimmunol Neuroinflamm 2020; 8(1): e928.
[http://dx.doi.org/10.1212/NXI.0000000000000928] [PMID: 33277427]
[34]
Dahbour S, Jamali F, Alhattab D, et al. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neurosci Ther 2017; 23(11): 866-74.
[http://dx.doi.org/10.1111/cns.12759] [PMID: 28961381]
[35]
Harris VK, Stark J, Vyshkina T, et al. Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine 2018; 29: 23-30.
[http://dx.doi.org/10.1016/j.ebiom.2018.02.002] [PMID: 29449193]
[36]
Sharifzadeh N, Ghasemi A, Tavakol Afshari J, et al. Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial. Asia-Pac Psychiatry 2021; 13(2): e12445.
[http://dx.doi.org/10.1111/appy.12445] [PMID: 33150703]
[37]
Tian C, Wang X, Wang X, et al. Autologous bone marrow mesenchymal stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture. Exp Clin Transplant 2013; 11(2): 176-81.
[http://dx.doi.org/10.6002/ect.2012.0053] [PMID: 22891928]
[38]
Wang Z, Luo Y, Chen L, Liang W. Safety of neural stem cell transplantation in patients with severe traumatic brain injury. Exp Ther Med 2017; 13(6): 3613-8.
[http://dx.doi.org/10.3892/etm.2017.4423] [PMID: 28588689]
[39]
Chen G, Wang Y, Xu Z, et al. Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy. J Transl Med 2013; 11(1): 21.
[http://dx.doi.org/10.1186/1479-5876-11-21] [PMID: 23351389]
[40]
Liu X, Fu X, Dai G, et al. Comparative analysis of curative effect of bone marrow mesenchymal stem cell and bone marrow mononuclear cell transplantation for spastic cerebral palsy. J Transl Med 2017; 15(1): 48.
[http://dx.doi.org/10.1186/s12967-017-1149-0] [PMID: 28235424]
[41]
Amanat M, Majmaa A, Zarrabi M, et al. Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: A randomized double-blind sham-controlled clinical trial. Stem Cell Res Ther 2021; 12(1): 439.
[http://dx.doi.org/10.1186/s13287-021-02513-4] [PMID: 34362453]
[42]
Wang X, Cheng H, Hua R, et al. Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: A preliminary clinical study. Cytotherapy 2013; 15(12): 1549-62.
[http://dx.doi.org/10.1016/j.jcyt.2013.06.001] [PMID: 24100132]
[43]
Wang X, Hu H, Hua R, et al. Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: Pilot study on the correlation of efficacy and hereditary factors. Cytotherapy 2015; 17(2): 224-31.
[http://dx.doi.org/10.1016/j.jcyt.2014.09.010] [PMID: 25593078]
[44]
Ahn SY, Chang YS, Kim JH, Sung SI, Park WS. Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr 2017; 185: 49-54.e2.
[http://dx.doi.org/10.1016/j.jpeds.2017.02.061] [PMID: 28341525]
[45]
Yang Y, Pang M, Du C, et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: A phase 1/2 pilot study. Cytotherapy 2021; 23(1): 57-64.
[http://dx.doi.org/10.1016/j.jcyt.2020.09.012] [PMID: 33218835]
[46]
Satti HS, Waheed A, Ahmed P, et al. Autologous mesenchymal stromal cell transplantation for spinal cord injury: A Phase I pilot study. Cytotherapy 2016; 18(4): 518-22.
[http://dx.doi.org/10.1016/j.jcyt.2016.01.004] [PMID: 26971680]
[47]
Albu S, Kumru H, Coll R, et al. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: A randomized controlled study. Cytotherapy 2021; 23(2): 146-56.
[http://dx.doi.org/10.1016/j.jcyt.2020.08.008] [PMID: 32981857]
[48]
Cheng H, Liu X, Hua R, et al. Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury. J Transl Med 2014; 12(1): 253.
[http://dx.doi.org/10.1186/s12967-014-0253-7] [PMID: 25209445]
[49]
Vaquero J, Zurita M, Rico MA, et al. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline. Cytotherapy 2018; 20(6): 806-19.
[http://dx.doi.org/10.1016/j.jcyt.2018.03.032] [PMID: 29853256]
[50]
Karamouzian S, Nematollahi-Mahani SN, Nakhaee N, Eskandary H. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg 2012; 114(7): 935-9.
[http://dx.doi.org/10.1016/j.clineuro.2012.02.003] [PMID: 22464434]
[51]
Vaquero J, Zurita M, Rico MA, et al. Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury. Cytotherapy 2017; 19(3): 349-59.
[http://dx.doi.org/10.1016/j.jcyt.2016.12.002] [PMID: 28089079]
[52]
Hur JW, Cho TH, Park DH, Lee JB, Park JY, Chung YG. Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: A human trial. J Spinal Cord Med 2016; 39(6): 655-64.
[http://dx.doi.org/10.1179/2045772315Y.0000000048] [PMID: 26208177]
[53]
Pal R, Venkataramana NK, Bansal A, et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: A pilot clinical study. Cytotherapy 2009; 11(7): 897-911.
[http://dx.doi.org/10.3109/14653240903253857] [PMID: 19903102]
[54]
Singer W, Dietz AB, Zeller AD, et al. Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology 2019; 93(1): e77-87.
[http://dx.doi.org/10.1212/WNL.0000000000007720] [PMID: 31152011]
[55]
Jin JL, Liu Z, Lu ZJ, et al. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res 2013; 10(1): 11-20.
[http://dx.doi.org/10.2174/156720213804805936] [PMID: 23151076]
[56]
Feldmesser M. Fungal disease following contaminated steroid injections: Exserohilum is ready for its close-up. Am J Pathol 2013; 183(3): 661-4.
[http://dx.doi.org/10.1016/j.ajpath.2013.06.010] [PMID: 23876717]
[57]
Kauffman CA, Malani AN. Fungal infections associated with contaminated steroid injections. Microbiol Spectr 2016; 4(2): 4.2.23.
[http://dx.doi.org/10.1128/microbiolspec.EI10-0005-2015] [PMID: 27227303]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy